LP
ATRS

LMR Partners’s Antares Pharma, Inc. ATRS Stock Holding History

LMR Partners’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-37,490
Closed -$126K – 513
2018
Q3 		$126K Buy
+37,490
New +$116K 0.01% 318
2016
Q3 		– Sell
-282,738
Closed -$297K – 524
2016
Q2 		$297K Buy
+282,738
New +$273K 0.05% 346

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LMR Partners's ATRS Position: Q4 2018 in Review

LMR Partners sold out of Antares Pharma, Inc. (ATRS) in Q4 2018, closing a stake of 37,490 shares — an estimated $126K sold.

LMR Partners first reported a position in ATRS in Q2 2016 and held it in 2 quarters. The position peaked at $297K in Q2 2016. 120 funds tracked by Wall St. Rank hold ATRS as of Q4 2018.

  • LMR Partners reported no remaining Antares Pharma, Inc. position as of Q4 2018 after selling out during the quarter.
  • LMR Partners sold 37,490 Antares Pharma, Inc. shares in Q4 2018, an estimated $126K.
  • LMR Partners first reported a position in Antares Pharma, Inc. in Q2 2016 and held it in 2 quarters.
  • LMR Partners's Antares Pharma, Inc. position peaked at $297K in Q2 2016.
  • 120 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2018.

Based on LMR Partners's 13F filing for Q4 2018, filed 14 Feb 2019.